Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 1.00 |
| ▸ | QTRT1 | Q9BXR0 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TYMS | P04818 | 4/20 | 0.42 |
| ▸ | PNP | P00491 | 3/20 | 0.42 |
| ▸ | TYMP | P19971 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25394322 | 0.98 | DYRK1A (0.96) | DYRK1AQTRT1MAPTKDM4EALDH1A1 | |
| SCHEMBL14228146 | 0.78 | DYRK1A (0.64) | DYRK1AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL7014736 | 0.77 | DYRK1A (0.62) | DYRK1AKDM4EALDH1A1LMNAHSD17B10 | |
| SCHEMBL15693107 | 0.77 | DYRK1A (0.62) | DYRK1ATYMPGSK3BBACE1ADORA2A | |
| SCHEMBL28309711 | 0.77 | DYRK1A (0.62) | DYRK1AKDM4EALDH1A1LMNAHSD17B10 | |
| SCHEMBL7851729 | 0.77 | DYRK1A (0.62) | DYRK1AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL7164003 | 0.75 | DYRK1A (0.60) | DYRK1ATYMPGSK3BBACE1ADORA2A | |
| SCHEMBL19221872 | 0.73 | DYRK1A (0.58) | DYRK1ATYMPGSK3BBACE1ADORA2A | |
| SCHEMBL16212529 | 0.73 | DYRK1A (0.57) | DYRK1ATYMPGSK3BBACE1ADORA2A | |
| SCHEMBL18961718 | 0.73 | DYRK1A (0.57) | DYRK1AMAPTKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4188553-B1 | COMPOUNDS | PROVOST FELLOWS FOUND SCHOLARS & OTHER MEMBERS BOARD COLLEGE HOLY & UND (IE) | 2024-05-08 | — | — | EP | claimed |
| CN-116783197-A | Compounds of formula (I) | 都柏林圣三一学院教务长、研究员、基金会学者及董事会其他成员 | 2023-09-19 | — | — | CN | claimed |
| WO-2001073438-A1 | RICIN INHIBITORS AND METHODS FOR USE THEREOF | RESEARCH DEVELOPMENT FOUNDATION (US) | 2001-10-04 | — | — | WO | claimed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | disclosed |
| EP-3854799-B1 | CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION | SHANGHAI DE NOVO PHARMATECH CO LTD (CN) | 2024-07-17 | — | — | EP | disclosed |
| CN-116783197-A | Compounds of formula (I) | 都柏林圣三一学院教务长、研究员、基金会学者及董事会其他成员 | 2023-09-19 | — | — | CN | disclosed |
| WO-2023060858-A1 | MONOCHROMATIC FLUORESCENCE MRT GENE SEQUENCING REAGENT AND METHOD BASED ON ENVIRONMENT-SENSITIVE DYE | 深圳铭毅智造科技有限公司 | 2023-04-20 | — | — | WO | disclosed |
| WO-2023280156-A1 | MODIFIED NUCLEOSIDE OR NUCLEOTIDE | 深圳华大生命科学研究院 | 2023-01-12 | — | — | WO | disclosed |
| US-11548909-B2 | Methods of using nucleotide analogues | IsoPlexis Corporation (US) | 2023-01-10 | — | — | US | disclosed |
| WO-2022261029-A2 | PEPTIDE NUCLEIC ACID THERAPEUTICS FOR TRINUCLEOTIDE REPEAT DISORDERS | NEUBASE THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022261030-A1 | OLIGONUCLEOTIDE ANALOGUE MODULATORS OF ONCOGENES | NEUBASE THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| EP-0923287-A4 | NONCLASSICAL PYRROLO 2,3-D]PYRIMIDINE ANTIFOLATES | LILLY CO ELI (US) | 2001-08-01 | — | — | EP | disclosed |
| EP-0923287-A1 | NONCLASSICAL PYRROLO 2,3-D]PYRIMIDINE ANTIFOLATES | ELI LILLY AND COMPANY (US) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998008382-A1 | NONCLASSICAL PYRROLO[2,3-D]PYRIMIDINE ANTIFOLATES | ELI LILLY AND COMPANY (US) | 1998-03-05 | — | — | WO | disclosed |
| US-5594121-A | DETECT VIRUSES, DISEASES | GILEAD SCIENCES, INC. (US) | 1997-01-14 | — | — | US | disclosed |
| EP-0695306-A1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PURINES | GILEAD SCIENCES, INC. (US) | 1996-02-07 | — | — | EP | disclosed |
| WO-1994024144-A2 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PURINES | GILEAD SCIENCES, INC. (US) | 1994-10-27 | — | — | WO | disclosed |
| CN-1078235-A | Medicinal compound | LILLY CO ELI (US) | 1993-11-10 | — | — | CN | disclosed |
| EP-0567223-A1 | Glutamic acid derivatives as antineoplastic agents | ELI LILLY AND COMPANY (US) | 1993-10-27 | — | — | EP | disclosed |
| US-5196424-A | Antitumor | ELI LILLY AND COMPANY (US) | 1993-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | DYRK1A 2425/4885QTRT1 1282/4885MAPT 3447/4885 |
| US-11548909-B2 | Methods of using nucleotide analogues | NT5C3B, SAMHD1, RNGTT | DYRK1A 4485/4885QTRT1 472/4885MAPT 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.